+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
ALIVUS

Alivus Life Sciences Share Price

₹1,388.90 +22.6 (1.65%)
New 52W High in past week

07 Sep, 2026 3:53 PM (IST)

Alivus Life Sciences live price: ₹1,388.90. It opened at ₹1,377 vs previous close ₹1,366; intraday high/low: ₹1,420/₹1,361. The 50 & 200 DMA stand at ₹1,278.30/₹1,103.80.

Alivus Life Sciences Performance

  • Today's Low
  • ₹1,361
  • Today's High
  • ₹1,420
  • 52 Week Low
  • ₹819
  • 52 Week High
  • ₹1,494
  • Open Price₹1,377
  • Previous Close₹1,366
  • Volume136,773
  • 50 DMA₹1,278.30
  • 100 DMA₹1,188.70
  • 200 DMA₹1,103.80

Alivus Life Sciences Chart

Investment Returns

  • Over 1 Month + 4.81%
  • Over 3 Month + 34.52%
  • Over 6 Month + 51.78%
  • Over 1 Year + 50.48%

Smart Investing Starts Here Start SIP with Alivus Life Sciences for Steady Growth!

Invest Now

Alivus Life Sciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 28.3
  • PEG Ratio
  • 1.3
  • Market Cap Cr
  • 17,052
  • P/B Ratio
  • 4.9
  • Average True Range
  • 55.4
  • EPS
  • 49.1
  • Dividend Yield
  • 0.4
  • MACD Signal
  • 39.6
  • RSI
  • 58.13
  • MFI
  • 62.44

Latest Stock News Updates

Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Enclosed please find herewith Investor meet details.

Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meetings

Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Enclosed please find herewith Press Release with respect to Acquisition.

Alivus Life Sciences Financials

Alivus Life Sciences Technicals

EMA & SMA

Current Price
₹1,388.90
+ 22.6 (1.65%)
pointer
  • Bearish Moving Average 2
  • Bullish Moving Average 14
  • 20 Day
  • ₹1,362.80
  • 50 Day
  • ₹1,278.30
  • 100 Day
  • ₹1,188.70
  • 200 Day
  • ₹1,103.80

Resistance and Support

1389.87 Pivot Speed
  • R3 1,477.40
  • R2 1,448.60
  • R1 1,418.70
  • S1 1,360.00
  • S2 1,331.20
  • S3 1,301.30

Alivus Life Sciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-07-30 Quarterly Results
2026-05-14 Audited Results & Final Dividend
2026-01-22 Quarterly Results
2025-11-06 Quarterly Results
2025-08-01 Quarterly Results
Date Purpose Remarks
2026-09-01 FINAL Rs.5.00 per share(250%)Final Dividend
2025-09-01 FINAL Rs.5.00 per share(250%)Final Dividend
2023-10-17 INTERIM Rs.22.50 per share(1125%)Interim Dividend
2023-03-24 INTERIM Rs.21.00 per share(1050%)Interim Dividend
2021-11-23 INTERIM Rs.10.50 per share(525%)Interim Dividend
View Alivus Life Sciences Dividend History Arrow

Alivus Life Sciences Shareholding Pattern

74.87%
12.42%
5.65%
5.54%
1.53%

About Alivus Life Sciences

Alivus Life Sciences is primarily engaged in the development, manufacture, and marketing of active pharmaceutical ingredients. View More
  • NSE Symbol
  • ALIVUS
  • BSE Symbol
  • 543322
  • Executive Director,Managing Director,Chief Executive Officer
  • Yasir Yusufali Rawjee
  • ISIN
  • INE03Q201024

Similar Stocks to Alivus Life Sciences

Alivus Life Sciences FAQs

Alivus Life Sciences share price is ₹1,388 As on 07 September, 2026 | 21:24

The Market Cap of Alivus Life Sciences is ₹17051.7 Cr As on 07 September, 2026 | 21:24

The P/E ratio of Alivus Life Sciences is 28.3 As on 07 September, 2026 | 21:24

The PB ratio of Alivus Life Sciences is 4.9 As on 07 September, 2026 | 21:24

The 52 week High & Low of Alivus Life Sciences is ₹1493.8/₹819 respectively As on 07 September, 2026 | 21:24

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23